The preventive vaccinations play an important role to maintain the sustainable health of people. The vaccine supports the body’s immune system to fight future infections or diseases. These vaccines consist of weakened or killed bacterial or microbial DNA. After the vaccination, the immune system produces antibodies. It is relatively very harmless, agent-specific, and antigenic components that induce the protective-immunity against corresponding infectious agent. Preventive vaccines are mainly targeted at people of different age groups and can strengthen their lifelong immune systems. Preventive vaccination can prevent certain infectious diseases.
As per analysis, “Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” the leadin players operating in the Asia-Pacific preventive vaccines market include GlaxoSmithKline plc, Emergent BioSolutions Inc., China National Biotec Group Company Ltd., Takeda Pharmaceutical Co. Ltd., Merck & Co., Sanofi SA, Johnson & Johnson, Novavax, Inc., CSL Ltd., Bavarian Nordic A/S, Moderna Inc., Daiichi Sankyo Co. Ltd, AstraZeneca plc and among others. Major market players focus on mergers, partnerships and acquisitions, with strong focused on Research & Development (R&D) for the product innovation for new diseases.
By administration, the preventive vaccines market can be divided into pediatric vaccine and adult vaccine. Pediatric vaccine segment holds major share in market as children are more prone to the infectious disease among other owing to developing immune system and therefore needs the proper vaccination. Additionally, by diseases type, market can be divided into measles, mumps & varicella, pneumococcal disease, DPT, hepatitis, typhoid and influenza. Hepatits segment is expected to exhibit substantial growth rate caused by increase in incidence of the disease & infections and presence of preventive vaccine during the forecast period.
Increase in prevalence of infectious diseases is a key factor for growth of the market. Additionally, growth in government support for vaccine development is an important factor to fueling the demand for preventative vaccine. Government are taking various initiatives to provide better life, thus the government in many countries provide free vaccine to prevent from various diseases like polio and many others which trigger the growth of market. However, factors including complications associated with preventive vaccines procedures and high cost of vaccine development may impact the market. Moreover, preventive vaccines have reached at the maturity in some of the disease for instance polio, measles, mumps, chicken pox, rubella and influenza. Furthermore, growth in research activities coupled with new product launches is a major trend for market.
In Asia-Pacific region, the pediatric vaccine segment is projected to grow with the highest growth owing to increase in government awareness program for the child vaccination during the forecast period. Due to increased investment in advanced vaccines and R&D during the forecast period, Japan leads the regional market growth rate, and the pediatric vaccine sector has a dominant position in the region. It is estimated that future of the market will be optimistic because of increase in awareness about preventive care, growth in innovative technology in vaccine development and increase in funding from government & international organizations during the forecast period.
For More Information, click on the link below:-
Ankur Gupta, Head Marketing & Communications